MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Arena Pharmaceuticals Company Profile (NASDAQ:ARNA)

Consensus Ratings for Arena Pharmaceuticals (NASDAQ:ARNA) (?)
Ratings Breakdown: 1 Sell Rating(s), 3 Hold Rating(s), 2 Buy Rating(s)
Consensus Rating:Hold (Score: 2.17)
Consensus Price Target: $6.88 (168.55% upside)

Analysts' Ratings History for Arena Pharmaceuticals (NASDAQ:ARNA)
Show:
DateFirmActionRatingPrice TargetActions
5/14/2015BMO Capital MarketsReiterated RatingMarket Perform$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/13/2015Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/12/2015WallachBeth CapitalLower Price TargetBuy$8.00 -> $6.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
2/2/2015Piper JaffrayReiterated RatingOverweight$7.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/22/2015RBC CapitalInitiated CoverageSector Perform$5.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
1/7/2015BMO Capital MarketsReiterated RatingPositiveView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/30/2014BMO Capital MarketsReiterated RatingMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/4/2014Credit SuisseInitiated CoverageUnderperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
8/7/2014WallachBeth CapitalLower Price TargetBuy$9.00 -> $8.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/24/2014Wells Fargo & Co.Initiated CoverageMarket PerformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/15/2013WallachBeth CapitalInitiated CoverageBuy$9.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2013Leerink SwannReiterated RatingOutperform$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
11/11/2013Jefferies GroupReiterated RatingBuy$12.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/16/2013Needham & Company LLCReiterated RatingHoldView Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/3/2013Cowen and CompanyInitiated CoverageMarket Perform$4.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/30/2013Credit SuisseLower Price TargetUnderperform$5.00 -> $4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 9/2/2013 forward)
            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha